Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Xenium In Situ Services are Now Available
Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Advancing In Vitro Disease Modeling with Mouse Hepatocytes for Gene Therapy
White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Xenium In Situ Services are Now Available
Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Advancing In Vitro Disease Modeling with Mouse Hepatocytes for Gene Therapy